Immuron Ltd — Regulatory Filings 2006

Feb 28, 2006

March 1st, 2006

Company Announcement Office Australian Stock Exchange Ltd (ASX) 4^th Floor, 20 Bridge Street Sydney NSW 2000

Dear Sir/Madam

Please find herewith a company announcement "EV-71 Preventative Commercialisation Update" for release and distribution to the market immediately.

Yours sincerely

CONOR GRAHAM Managing Director & CEO

EV-71 Preventative Commercialisation Update

Anadis is releasing this update in response to the many enquires regarding the Company's commercialisation program for' a hyperimmune colostrum based product against Enterovirus 71 (the "EV-71" project).

Enterovirus 71 is a life threatening, polio like, disease that is of particular threat to children. Anadis is using its hyperimmune colostrums technology to urgently produce a product that can help health authorities control the spread of disease especially amongst children.

Working with the health industry in Taiwan

During November 2002, Anadis signed a development and manufacturing agreement with the Taiwanese Development Centre for Biotechnology (DCB) for the development of a preventative therapy against Enterovirus 71. The concept was to develop a hyperimmune colostrum antibody based preventative, when taken daily during the high risk period (summer months), would provide a "suit of amour" against an infection. The DCB had estimated a dosage requirement at a conservative 30-35% penetration of the potential market in Taiwan - this equated to over 110 million doses per annum.

By mid August 2004 – less than 2 years later – Anadis had developed a laboratory scale protective therapy against Enterovirus 71, an almost unheard of achievement in terms of development time.

In June 2005 Anadis announced that it had successful obtained bioactive proteins against Enterovirus 71 from cows – commercial quantity scale up was proven to be possible. Since this time Anadis has been rigorously working on this large scale commercialisation project.

EV-71 Preventative Production & Commercialisation Timeline

Note: While every effort has been made to ensure these dates are correct. Anadis can not be responsible for delays due to circumstances beyond its control.

The most challenging steps in the product Development timeline have been accomplished and the way looks open for Anadis to have the Enterovirus 71 preventative to market, in Taiwan, in time for the Northern Hemisphere summer of 2007 (July 2007).

Initial production is aimed at approximately 20 million doses, set to grow rapidly once demand increases. Other key markets which are being looked at in the short term include China, which will be targeted to begin during the summer of 2008.

Anadis is currently in discussions with a significant number of potential Taiwanese distributors for this product, along with the opportunity to distribute other Anadis products, such as Travelan.

This is an exciting time for Anadis as this project offers the potential to contribute very significantly to the revenue of the company during the 2006/07 financial year.

About Enterovirus 71

Enterovirus 71, a polio like disease, is one of the viruses that cause 'hand, foot and mouth' or 'slapped cheek' disease in young children. Mild symptoms usually include a rash and quieter than normal behavior, while a significant proportion of younger children can develop nervous signs such as fits, paralysis and even death. Fatalities can occur for approximately one quarter of the children affected by the severe form of the disease.

Although not well known Enterovirus 71 is a major problem in the Asia-Pacific region – in particularly Taiwan and China – outbreaks have also been reported in Hong Kong, Vietnam, Malaysia and Singapore

During 2005, Enterovirus 71, was responsible for the infection of over fifty children and the tragic death of five. Enterovirus 71 is an emerging 'disease state', and the World Health Organisation are comparing the disease with the spread of polio in Europe and North America in the late 19th century.

About Anadis Limited:

Anadis, a Melbourne based biopharmaceutical company is focused on Nutraceutical and Pharmaceutical research and development. Anadis is a specialist in the development of bovine colostrum derived products for therapeutic use in humans. Projects include:

Anadis' first commercialised product: Travelan is a natural product, which significantly decrease the risk of the medical condition known as Travellers Diarrhoea and the symptoms of gastrointestinal disorders. Travelan is a bovine colostrum preparation, prepared from cows hyper-immunized against the 13 most common strains of $E_{\text{col}}i$ – the most common cause of Travellers Diarrhoea (Bali Belly, Delhi Belly, etc.).

Travelan has recently received a "Green Light' for sales in the US and a distributor in Canada has been appointed. Travelan is being considered for other markets including: Singapore, India, Korea, United Arab Emirates, Thailand, Malaysia, South Africa and the UK and EU.

Travelan has recently been potentially identified for additional gastrointestinal indications including Irritable Bowel Syndrome IBS and Inflammatory Bowel Disorder IBD.

For more information please visit www.travelan.com.au

EV-71 - a bioactive protein based preventative product against Enterovirus 71, a debilitating polio like disease, is one of the viruses that causes 'hand, foot and mouth' or 'slapped cheek' disease. A significant proportion of younger children effected can develop nervous signs such as fits, paralysis and Enterovirus 71 has the potentially to be fatal.

A set of Bio-Warfare/Respiratory Protection technologies, a project in conjunction with the Australian Department of Defence and US Bio-Defence Organisations, initially focused on short-term immediate protection from airborne bacteria such as Anthrax and Plague, future civilian applications include Hay .
Fever and Asthma.

Bio-Shield 10 a range of "bio-shielding" technologies which protect delicate molecules, enzymes and proteins, initially targeted for use in the pro-biotic market.

Development into an Immune Stimulating Infant Formula is underway, initially destined for the Asian market.

Pyloran, which has been clinically proven to reduce levels of H.pylori bacteria in the stomach and reduce the symptoms of H.pylori associated gastritis - Anadis is also in early development of a H.pylori vaccine.

For further information, please contact:

Conor Graham - Chief Executive Officer Email: conor.g@anadis.com.au +61 3 9358 6388 Arie Nudel -- Investor Relations Email: arie.n@anadis.com.au +61 3 9358 6388

Visit our websites: www.anadis.com.au and www.travelan.com.au

Anadis - Delivering On The Promise Of Biotechnology